The following discussion and analysis of financial condition and results of
operations relates to the operations and financial condition reported in our
consolidated financial statements, which appear elsewhere in this Report, and
should be read in conjunction with such financial statements and related notes
included in this Report. Except for the historical information contained herein,
the following discussion, as well as other information in this Report, contain
"forward-looking statements," within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the Securities Exchange
Act of 1934, as amended, and are subject to the "safe harbor" created by those
sections. Actual results and the timing of the events may differ materially from
those contained in these forward-looking statements due to many factors,
including those discussed in the "Forward-Looking Statements" set forth
elsewhere in this Report.
Overview
Heyu Biological Technology Corporation (the "Company" or "we") was incorporated
in the state of Nevada on May 18, 1987, as Asphalt Associates, Inc. and changed
its name to Pacific WebWorks in January 1999. From 1999 to 2016, the Company
engaged in the development and distribution of web tools software, electronic
business storefront hosting, and Internet payment systems for individuals and
small to mid-sized businesses.
On July 3, 2018, the Company changed its name to Heyu Biological Technology
Corporation and applied for a new ticker symbol HYBT.
On January 17, 2019, Jiashierle (Xiamen) Healthcare Technology Co., Ltd.
("JSEL"), a limited liability company organized under the laws of the People's
Republic of China (the "PRC"), and an indirect wholly owned subsidiary of the
Company, entered into a Share Transfer Agreement (the "Share Transfer
Agreement") with Mr. Yu Xu ("Mr. Xu"), an individual who owned 90% of the equity
interests of Shanghai Kangzi Medical Technology Co., Ltd., a limited liability
company organized under the laws of the PRC ("Kangzi"). Pursuant to the Share
Transfer Agreement, Mr. Xu transferred 60% of the equity interests of Kangzi to
JSEL on January 17, 2019 for the purpose of developing a joint venture in the
business of selling medical equipment. In return, JSEL would fund the operations
of Kangzi in proportion to its equity interest in Kangzi. Kangzi owned no assets
and conducts no business operation of its own. As a result, as of January 17,
2019, Kangzi became an indirect subsidiary of the Company.
Since the beginning of 2019, Mr. Xu has led the core research and development
team of Kangzi to develop and manufacture a new medical product, the
Submillimeter Wave (Terahertz) Quantized Space Therapy Chamber (the "Chamber").
Utilizing submillimeter waves, the Chamber is a medical equipment designed to
treat cancer through cold nuclear fusion caused by cosmic ray muons in an
enclosed chamber. Specifically, we believe that exposure to an appropriate
amount of submillimeter waves could accelerate the generation of a large number
of cosmic ray muons inside the human body and that such cosmic ray muons could
further facilitate cold nuclear fusion, which could reverse the process of
cancer by converting selenium into nickel inside cells.
14
The core research and development team consists of researchers who have
extensive experience in medicine and physics. The lead scientist of the team,
Mr. Xu, served as the deputy chief engineer of the New Energy Base of the
National Defense-Science and Technology Commission in 1995, the director of
Shanghai Hengbian New Energy Research Institute from 2003 to 2008, and the
chairman and chief scientist of Shanghai Guangzhui New Energy Technology Co.,
Ltd. from 2011 to 2019. In 2012, Mr. Xu was awarded the "Harmony Person of the
Year in China" at the "2011 Harmony China Annual Summit" in Beijing. He was also
jointly recognized as "Leaping China: One of the Most Influential People of the
Year in 2011" by China International Economic and Technical Cooperation
Promotion Association, China Elite Culture Promotion Association, and China
Outstanding Chinese Merchants Association. In 2013, the Organizing Committee of
Boau Forum on Asian Small and Medium Enterprise Development awarded Mr. Xu "2013
China Economic Outstanding Contribution Award."
Pursuant to the terms of the Share Transfer Agreement, JSEL has the right to
monitor and manage all aspects of operation of Kangzi, including its research
and development activities relating to the Chamber. As the development of the
Chamber enters its final stage at Kangzi, JSEL started accepting pre-orders for
the Chamber in September 2019. On October 15, 2019, JSEL entered into a clinical
cooperation agreement (the "Clinical Cooperation Agreement") with Shenzhen
Saikun Biotechnology Co., Ltd. ("Saikun"). Pursuant to the Clinical Cooperation
Agreement, Saikun agreed to pay JSEL RMB5.5 million as the total pre-order
payment. RMB1.5 million and RMB1.5 million were delivered to JSEL on September 7
and September 27, 2019, respectively. The parties are currently working on the
timing for payment of the remaining RMB2.5 million due under the Clinical
Cooperation Agreement. In exchange, JSEL is obligated to purchase all the
components of a Chamber from Kangzi, fully assemble it, and conduct a clinical
trial with Saikun, third-party hospital partners, and patients using the
Chamber. Specifically, after receiving the full amount of payment from Saikun,
JSEL shall transport the Chamber to Saikun's preferred location, properly
install it, and conduct a clinical trial that lasts at least one month. During
the clinical trial, JSEL shall provide training sessions regarding the proper
operation of the Chamber to Saikun's employees. Both Saikun and JSEL are
obligated to find third-party hospitals that will agree to act as partners to
co-host the clinical trial and patients who will voluntarily undergo treatment
provided by the Chamber. While Saikun is responsible for various expenses
related to the clinical trial, JSEL is responsible for communicating with
patients receiving treatment and other patient-related administrative matters.
When JSEL determines that Saikun is capable of properly operating the Chamber
and managing activities related to the Chamber, Saikun may request JSEL to move
the Chamber to a location designated by Saikun and reinstall it. Furthermore,
upon the successful completion of the clinical trial, JSEL shall provide Saikun
governmental permits necessary for the operation of the Chamber, and Saikun
shall operate the Chamber and provide related services to patients under the
supervision of JSEL. In addition, JSEL shall transfer the right of using the
Chamber and any beneficiary right affiliated with using the Chamber to Saikun
upon receiving the full amount of payment from Saikun. JSEL, nevertheless, owns
all the intellectual property rights affiliated with the Chamber. If the two
parties decide to terminate the Clinical Cooperation Agreement prior to the
expiration of its term, Saikun's right of using the Chamber during the term is
still effective as long as its use of the Chamber does not infringe any of
JSEL's intellectual property rights affiliated with the Chamber. The two parties
agreed that the term of the Clinical Cooperation Agreement would not end until
Kangzi successfully obtains permits issued by relevant government entities
supervising development and sale of medical equipment.
To prepare for mass production of the Chambers, Kangzi is conducting clinical
experiments to make further improvements on the Chamber and adjusting features
of the mass-production mold for the Chambers. As its long-term business
strategy, Kangzi focuses on researching, developing, and manufacturing
high-technology medical equipment while targeting both individual and
institutional customers. It plans to mass-produce the Chambers in small and
medium sizes, establish operation centers to sell the Chambers in various cities
across China, and initiate advertising and marketing campaigns on different
media platforms. Kangzi will also monetize on services provided to customers who
use the Chambers and other medical products. As of the date of this Report, we
are still in the clinical experiment phase and Kangzi is still in the process of
obtaining official governmental permits from relevant government authorities to
produce and sell the Chambers on a national scale. There is no assurance that we
will obtain the official governmental permits.
15
In addition to business activities related to the Chamber, the Company is also
conducting research, development, manufacturing, and sale of healthcare
equipment and plant-based disinfectant spray for treating skin infections and
disinfecting wounds. On March 17, 2020, we entered into a business service
cooperation agreement with Xiamen Qingda Intelligent Technology Co., Ltd., a
wholly-owned subsidiary of Cross-strait Tsinghua Research Institute, pursuant to
which the parties agreed to jointly improve a plant-based disinfectant spray for
treating skin infections and disinfecting wounds. The term of such agreement is
three years, and the agreement can be renewed upon mutual agreement of both
parties. The original plant-based disinfectant spray was developed and owned by
the Company, while the improved product shall be owned by both the Company and
Cross-strait Tsinghua Research Institute. The Cross-strait Tsinghua Research
Institute will receive 2% of the gross proceeds from sales of such improved
product. By September 30, 2020, we had generated revenues of approximately
$21,796 through sales of the improved product. In the near future, the Company
aims to standardize the production and sale of healthcare equipment and
plant-based disinfectant spray, while increasing its brand awareness in the
healthcare markets.
The recent COVID-19 outbreak has spread throughout the world, especially in
China, the United States, and Europe. On March 11, 2020, the World Health
Organization declared COVID-19 a pandemic-the first pandemic caused by a
coronavirus. The outbreak has resulted in the implementation of significant
governmental measures, including lockdowns, closures, quarantines, and travel
bans, intended to control the spread of the virus, which measures have caused
severe disruptions to our business operations. We suspended our business
operation in early February 2020 due to government mandates and most of our
staff members were forced to work from home. We partially resumed our business
operations on February 17, 2020, and we fully resumed our business operations on
March 1, 2020. However, as of the date of this Report, our management and
scientists have been working remotely. Accordingly, our business, results of
operations, and financial condition during the fiscal year ending December 31,
2020 have been adversely affected. As of the date of this Report, the COVID-19
outbreak seems to be under relative control in China and our management expects
that our results of operations will improve in the coming fiscal quarter.
Liquidity and Capital Resources
As of September 30, 2021, we had assets of $72,768, which consisted of current
assets of $4,353 in cash, $65,070 in other receivables, $3,345 as advances to
suppliers, and noncurrent asset of $76,065 as operating lease right-of-use
asset. We had liabilities of $1,916,930, which consisted of current liabilities
of $17,121 in accounts payable, $327,560 in accrued expenses and other payables,
$464,634 in advances from customers, $17 in taxes payable, $1,028,959 in related
party payables, and $78,639 in short-term operating lease liabilities. We had an
accumulated deficit of $19,599,039.
As of December 31, 2020, we had assets of $194,294, which mainly consisted of
$5,489 in cash and cash equivalents, and $134,315 in operating lease
right-of-use. As of December 31, 2020, we had liabilities of $1,762,125, which
mainly consisted of $17,871 in accounts payable, $459,583 in advances from
customers, $32 in other taxes payables, $909,884 in related party payables, and
$56,570 in operating lease liabilities. We also had an accumulated deficit of
$19,458,101. Since we started our business operations in March 2019, our
director, Mr. Hungseng Tan, has been advancing the Company's daily operating
expenses.
In light of the impacts of the COVID-19 outbreak, if we are required to operate
in a challenging economic environment in China, or incur unanticipated capital
expenditures, or decide to accelerate growth, we may need additional financing.
As of September 30, 2021, we had borrowed a total of $1,028,959 from a
shareholder for working capital purposes. The loan is unsecured, non-interest
bearing and payable on demand. We cannot guarantee, however, that additional
financing, if required, would be available on favorable terms, if at all. Such
financing may include the use of additional debt or the sale of the Company's
equity interests. Any financing which involves the sale of the Company's equity
interests or instruments that are convertible into the Company's equity
interests could result in immediate and possibly significant dilution to our
existing shareholders.
16
Results of Operations
Comparison of the Three Months Ended September 30, 2021 and 2020
Our revenues during the three months ended September 30, 2021, were $24,784, and
cost of revenues was $7,327, as compared to revenues of $16,600 and cost of
revenues $5,543 for the same period in 2020, respectively. The increase in our
revenue were mainly due to adjustment of our product line in reaction to the
COVID-19 outbreak.
We had incurred selling expenses of $522 and administrative expenses of $8,276
during the three months ended September 30, 2021, as compared to $301 and
$88,037 for the same period in 2020, respectively. The increase in selling
expenses was mainly due to more sales activities for our new products in the
quarter ended September 30, 2021 compared with the same period in 2020. The
decrease in administrative expenses was mainly due to decreased office rental
expenses and employment expenses during the period. We might incur operating
expenses without sufficient revenues, as we determined to focus on the research,
development, and manufacturing of healthcare equipment and products. We will
depend upon our officers and directors to make loans to the Company to meet any
costs that may occur. All such advances will be interest-free loans or equity
contributions.
Comparison of the Nine Months Ended September 30, 2021 and 2020
Our revenues during the nine months ended September 30, 2021, were $78,397, and
the cost of revenues was $24,069, as compared to $52,383 and $22,732 for the
same period in 2020, respectively. The increases in revenues and cost of
revenues were due to an adjustment of product line based on the impact of the
COVID-19 outbreak. As our prospective customers' businesses had been adversely
affected by the COVID-19 outbreak, the demand for our main products and services
decreased. As of the date of this Report, the COVID-19 outbreak seems to be
under relative control in China. We believe that the impact of the COVID-19
outbreak on our business is both temporary and limited, and our revenues will
start growing again as we resume our business activities.
We had incurred selling expenses of $1,208 and administrative expenses of
$193,905 during the nine months ended September 30, 2021, as compared to $6,527
and $280,134 for the same period in 2020, respectively. The decrease in selling
expenses was mainly due to fewer advertising expenses for our products during
the period. The decrease in administrative expenses was mainly due to decreased
office rental expenses and employment expenses during the period. We might incur
operating expenses without sufficient revenues, as we have recently determined
to focus on the research, development, and manufacturing of healthcare equipment
and products. We will depend upon our officers and directors to make loans to
the Company to meet any costs that may occur. All such advances will be
interest-free loans or equity contributions.
17
Going Concern
The accompanying financial statements are presented on a going concern basis.
The Company's financial condition raises substantial doubt about the Company's
ability to continue as a going concern. As of September 30, 2021, the Company
had an accumulated deficit of $19,599,039, and a net income of $8,661 and a net
loss of $140,938 for the three and nine months ended September 30, 2021,
respectively. It is relying on advances from its director, Mr. Hungseng Tan, to
meet its limited operating expenses.
In light of the impacts of the COVID-19 outbreak, if the economic environment in
China worsens, or if we incur unanticipated capital expenditures or decide to
accelerate growth, we may need additional financing. As of September 30, 2021,
we had borrowed a loan from a stockholder for working capital purposes. The loan
is unsecured, non-interest bearing and payable on demand. We cannot guarantee,
however, that additional financing, if required, would be available on favorable
terms, if at all. Such financing may include the use of additional debt or the
sale of the Company's equity interests. Any financing which involves the sale of
the Company's equity interests or instruments that are convertible into the
Company's equity interests could result in immediate and possibly significant
dilution to our existing stockholders.
Off-Balance Sheet Arrangements
We do not have any off-balance sheet arrangements that have or are reasonably
likely to have a current or future effect on our financial condition, changes in
financial condition, revenues, or expenses, results of operations, liquidity,
capital expenditures, or capital resources that is material to investors.
© Edgar Online, source Glimpses